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Malarial merozoites are released from infected erythro-
cytes, passing rapidly through the plasma to invade normal
erythrocytes. It has long been thought that antibodies di-
rected against merozoite surface proteins (MSPs) play an
important role in natural immunity against 
 
Plasmodium falci-
parum
 
 and that these antibodies may at least in part act
through blocking erythrocyte invasion by merozoites. In-
deed, such a view underpins much of the search for anti-
gens suitable for use as vaccines, targeting blood stage para-
sites, and has a major influence on ideas on the acquisition
of active immunity and on the passive protection of infants
through uptake of maternal antibodies. Although convinc-
ing evidence that antibodies from immune sera can clear an
infection has been obtained by passive transfer experiments
(1–4), IgG did not block invasion (3, 4). This paradox may
be explained by other actions of antibody such as clearance
of infected erythrocytes through recognition of 
 
P
 
. 
 
falci-
parum 
 
erythrocyte membrane protein 1 on their surface (5)
or through antibody-dependent cellular inhibition of para-
site growth (6). However, data are lacking on the effect of
passive transfer of IgG that has blocking antibodies.
Clearly antibodies can block invasion in vitro as has been
demonstrated with monoclonal and polyclonal antibodies
directed against merozoite antigens and with human anti-
bodies affinity purified on recombinant merozoite antigens
(7, 8). In keeping with the very short time that merozoites
are exposed before invasion, the antibody concentrations
required are high and are close to the upper limits of what
is possible in immune sera (9). Without using purified and
concentrated IgG, the maximum concentration of serum
that can be used in in vitro invasion assays is only 20% and
consequently, the antibodies are, at best, only 20% the con-
centration found in vivo. The assays for measuring parasite
growth rates in vitro are technically difficult with relatively
large errors. Thus, the levels of inhibition of parasite inva-
sion that may be highly significant in vivo are difficult to
reproducibly measure in vitro. The paper by O’Donnell et
al. in this issue (10) is important because it convincingly
demonstrates that most sera from two high transmission ar-
eas in Papua New Guinea are not only able to inhibit para-
site invasion in vitro but that much of that inhibition can
be attributed to antibodies directed against one protein,
MSP-1. This is a remarkable finding since, not only is
MSP-1 just one of thousands of proteins in the parasite, but
this activity is directed at a small portion of MSP-1: the
COOH-terminal 98 amino acids (MSP-1
 
19
 
) of the 
 
 
 
1,700
amino acid–long MSP-1.
In a few special cases, it has been possible to use a natu-
rally occurring deletion mutant or sequence variants to as-
sess the impact of a specific antibody on parasite growth.
For example, a deletion of the ring erythrocyte surface an-
tigen gene in the FCR-3 line of 
 
P. falciparum
 
 was used to
assess the relative importance of antibodies that reacted
with both the ring erythrocyte surface antigen and Ag332
proteins in blocking invasion (11).
In the paper by O’Donnell et al. in this issue, a pair of
matching parasite lines was generated by replacing the seg-
ment coding for the 
 
P. falciparum
 
 MSP-1
 
19
 
 portion of
MSP-1 by the orthologous gene segment from a rodent
malaria, 
 
P. chabaudi
 
, using allelic recombination. The 
 
P.
chabaudi
 
 MSP-1
 
19
 
 is sufficiently different to the 
 
P. falciparum
 
MSP-1
 
19
 
 in that antibodies are specific for one form or the
other, yet similar enough to allow the chimeric MSP-1
protein to be functional. As malaria parasites are haploid
during the blood stage, this single replacement creates a
parasite line genetically identical to its parent line, except
for the expression of MSP-1
 
19
 
. This allows the effect of
anti–MSP-1
 
19
 
 antibodies to be more accurately measured
than was previously possible. This is particularly important
for assessing the anti–MSP-1
 
19
 
 activity in the complex mix-
ture of antibodies with many different specificities to con-
served and polymorphic antigens in sera from people’s nat-
ural exposure to 
 
P. falciparum
 
. We expect that this
technique will be a valuable method for evaluating im-
mune responses for those malarial antigens where similar
replacements can be made.
Several other merozoite antigens, such as MSP-2, -3,
GLURP, ABRA, the apical membrane antigen 1, erythro-
cyte membrane antigen 175, and the rhoptry proteins
RAP-1 and RAP-2 are also under active consideration as
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targets of protective immunity (12). Presumably, other pro-
teins, as yet undescribed, also occur on merozoites. On the
assumption that different inhibitory specificities in the test
sera are additive, we calculate that the anti–MSP-1
 
19
 
 activ-
ity in the sera tested by O’Donnell et al. are responsible for
 
 
 
50% of the inhibition seen. This suggests that for natural
immunity, antibodies to this antigen may play a major role
in reducing parasite multiplication rates and, by implica-
tion, the burden of disease. If in vitro merozoite neutraliza-
tion indicates protection in vivo, then these data further
strengthen the belief that MSP-1
 
19
 
 is one of the top pros-
pects for an antimalarial vaccine to reduce death in Africa.
There is already considerable evidence from studies with
rodent malaria and from challenge studies with 
 
P. falciparum
 
in primates that vaccines based on MSP-1
 
19
 
 and on the
larger form of the antigen, MSP-1
 
42
 
, protect against malaria
(13). One of the concerns has been that protection in some
of these models is only obtained at very high antibody lev-
els and it has been unclear if these could be obtained or
maintained in humans. This paper now convincingly shows
that the level of antibody obtainable in natural infections is
sufficient to have a significant impact on parasite growth,
and presumably, the antibody is maintained by repeated
boosting of natural infections. In fact, considering that the
concentration of antibodies in the in vitro tests used by
O’Donnell et al. is only 5% of the concentration in the cir-
culation, one may wonder how some of these adults could
be infected at all.
Using the parasites developed by O’Donnell et al., it
may now be possible to follow the acquisition and loss of
invasion inhibiting immunity directed to MSP-1
 
19
 
 with
time. It will be interesting to reexamine the role of anti–
MSP-1
 
19 
 
in the age dependence of acquisition of immu-
nity. Early data showed that sera from adults in the Madang
area have a higher level of
 
 
 
in vitro inhibition than sera from
children (14). Of practical importance, these studies may
 
also enable the development of better in vitro correlates of
protection elicited by vaccines. In particular, the ability to
correlate levels of antibodies to specific MSP-1
 
19
 
 epitopes
with in vitro inhibition would facilitate the development of
optimum formulations and dosing regimens for human tri-
als. Other mechanisms of action of anti–MSP-1
 
19 
 
immunity
have been proposed. Now that a more defined assay is possible
for measuring the role of anti–MSP-1
 
19
 
 in in vitro–growth
inhibition, it may become possible to assign the relative im-
portance of antibody-mediated inhibition or merozoites
invasion and other protective mechanisms such as anti-
body-dependent cellular inhibition to the in vivo protec-
tion resulting from vaccination.
The observation by O’Donnell et al. that a significant
part of the in vitro invasion inhibitory activity of immune
human sera is directed against MSP-1
 
19
 
 provides direct ev-
idence that this part of MSP-1 may be under immune se-
lection pressure. Because this portion of the molecule can
be replaced by the ortholog from 
 
P. chabaudi
 
 which differs
by 57 of 98 amino acids (Fig. 1), O’Donnell et al. raise the
possibility in this issue and in an earlier paper (15) that the
apparent lack of strict sequence conservation required to
maintain function could allow the rapid selection of muta-
tions if this region is targeted by vaccines. Indeed some di-
versity is already found in this region of the 
 
P. falciparum
 
sequence (16).
In our view, there are several reasons why rapid selection
of escape mutants is unlikely. First, indirect evidence from
genotype frequencies determined by molecular epidemiol-
ogy suggests that variation in this region is primarily due to
genetic drift and is not under strong immune selection for
diversity (
 
F
 
ST
 
 
 
 
 
 0; references 17 and 18). Interestingly, all
monoclonal antibodies described to date that inhibit 
 
P. fal-
ciparum 
 
invasion
 
 
 
in vitro do not recognize variant sequences
(19, 20), although approximately half of all MSP-1
 
19
 
 mono-
clonal antibodies are variant specific (19). In some animals,
Figure 1. Alignment of the MSP-119 sequences from P. vivax (GenBank/EMBL/DDBJ accession no. AF91157), P. knowlesi H strain (GenBank/
EMBL/DDBJ accession no. AF298219), P. cynomolgi (GenBank/EMBL/DDBJ accession no. AAC46960), P. falciparum D10 cloned line (GenBank/
EMBL/DDBJ accession no. AAA29653), P. chabaudi adami (GenBank/EMBL/DDBJ accession no. AF149303), P. berghei ANKA (GenBank/EMBL/
DDBJ accession no AAF13063), and P. yoelii YM (GenBank/EMBL/DDBJ accession no AAA29702). Numbering commences from the start of the
MSP-119 fragment in P. falciparum. The arrow between amino acids 7 and 8 marks the junction of the P. falciparum–P. chabaudi MSP-119 chimera created
by O’Donnell et al. (reference 10). 
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recombinant MSP-1
 
19
 
 generates variant specific polyclonal
antibodies (13). Thus, although variant sequences are rec-
ognized, the dominant targets of protective immunity in
this molecule appear to be invariant.
Second, the constraints on the sequence may be much
greater than apparent from a comparison of the 
 
P. chabaudi
 
and 
 
P. falciparum
 
 sequences. The structure of MSP-1
 
19
 
 has
been determined from 
 
P. falciparum
 
 (21) and the 
 
P. cyno-
molgi
 
 ortholog (22). As expected from the primary se-
quence, MSP-1
 
19
 
 consists of two epidermal growth factor
(EGF) domains. As a result, the structure is highly con-
strained. MSP-1
 
19
 
 orthologs are known from seven species
and, other than 
 
P. cynomolgi
 
, from multiple isolates of each
species. Consistent with other studies (23), these sequences
fall into three clades: sequences from primate malarias (
 
P.
vivax
 
, 
 
P. knowlesi
 
, and 
 
P. cynomolgi
 
); sequences from P
 
. falci-
parum
 
; and sequences from rodent malarias (
 
P. chabaudi
 
, 
 
P.
berghei
 
, and 
 
P. yoelii
 
). A three-way comparison shows that
the variation between these sequences is not random, and
in many places, the three groups of sequences could be
considered to be chimeras of two archetype sequences (Fig.
1). For example, in the first 35 amino acids, the primate
and rodent sequences have identical or highly conserved
substitutions at positions 11, 14, 18, 23, 26, 30, and 31 that
differ from the 
 
P. falciparum
 
 sequence. On the other hand,
there are many places where the 
 
P. falciparum
 
 and the pri-
mate malaria sequences are similar but differ from the ro-
dent malaria sequences (e.g., amino acids 85, 86, 89, 91,
92, and 93 in the COOH-terminal portion of MSP-1
 
19
 
).
Overall, there are only 32 of 98 positions where the 
 
P. fal-
ciparum 
 
sequence does not follow the primate or rodent
malaria sequences. As suggested by O’Donnell et al., many
of the unique 
 
P. falciparum
 
 substitutions are apparently
linked. For example, examination of the structures of 
 
P. cy-
nomolgi
 
 MSP-1
 
19
 
 (22) and 
 
P. falciparum
 
 MSP-1
 
19
 
 (21) sug-
gests that replacement of the disulfide bond formed from
C
 
19
 
C
 
30
 
 in 
 
P. falciparum 
 
with V
 
14
 
W
 
30
 
 requires the replace-
ment of S
 
18
 
 with A
 
18
 
 to create the hydrophobic pocket sur-
rounding W
 
30
 
. In the available structures, there are few
amino acids not linked in this way. For example, K
 
10
 
 has a
side chain that projects out from the first EGF domain.
Even for these, their side chains may well interact with
other parts of the MSP-1 molecule or other interacting
proteins such as MSP-6 (24).
We come to a very different interpretation of the evolu-
tion of MSP-1
 
19
 
 to that proposed by O’Donnell et al. In
our view, much of the diversity in MSP-1
 
19
 
 is very ancient,
long predating the speciation that led to the current species.
Therefore, it is likely that even for the potentially greater
immune pressure induced by vaccination, functional con-
straints in the two EGF domains will substantially restrict
the generation of new sequence variants.
Of all candidate vaccines for preventing disease from 
 
P.
falciparum
 
 malaria, MSP-1
 
19/42
 
–based vaccines are consid-
ered leading candidates and are to be shortly tested in the
field. The discussion that we have presented argues for lim-
ited selection of mutants, even if the vaccine is effective in
reducing disease. Although we cannot predict its effective-
ness or the persistence of this efficacy in the coming years,
the assay devised by O’Donnell et al. will greatly facilitate
serologic tests for correlates of protection in the field. It
will be one measure of an immune response to correlate
with protection that may add power to the trial, similar to
the neutralization test employed by virologists.
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